Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma Exosomal MicroRNAs as Biomarkers for Suicidality and Ketamine Response
NCT02418195Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD), sponsored by University of Alabama at Birmingham. Started Apr 2015; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02418195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418195.